XML 23 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurement
9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurement Fair Value Measurement
Available-for-sale marketable securities consisted of the following (in thousands):
September 30, 2023
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Asset-backed securities$4,599 $— $(20)$4,579 
Corporate debt securities5,976 — (31)5,945 
U.S. treasury securities160,034 — (104)159,930 
Agency bonds16,020 — (73)15,947 
Commercial paper22,655 — (1)22,654 
Total marketable securities, available-for-sale$209,284 $— $(229)$209,055 
December 31, 2022
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Asset-backed securities$1,146 $— $— $1,146 
Corporate debt securities7,139 — (9)7,130 
U.S. treasury securities111,469 — (934)110,535 
Agency bonds2,783 (1)2,784 
Commercial paper7,004 — — 7,004 
Total marketable securities, available-for-sale$129,541 $$(944)$128,599 
As of September 30, 2023, 43 available-for-sale marketable securities with a fair market value of $196.8 million were in a gross unrealized loss position of $0.2 million. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of September 30, 2023 because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.
The estimated fair value of our contractual maturities of available-for-sale debt securities were as follows (in thousands):
September 30, 2023December 31, 2022
Due within one year$179,400 $114,353 
Due after one year but within five years29,655 14,246 
Total estimated fair value of contractual maturities, available-for-sale$209,055 $128,599 
The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):
September 30, 2023December 31, 2022
Level 1Level 2Total estimated fair valueLevel 1Level 2Total estimated fair value
Assets
Cash equivalents
Money market funds$147,113 $— $147,113 $191,704 $— $191,704 
U.S. treasury securities23,000 — 23,000 — — — 
Available-for-sale marketable
   securities
Asset-backed securities— 4,579 4,579 — 1,146 1,146 
Corporate debt securities— 5,945 5,945 — 7,130 7,130 
U.S. treasury securities159,930 — 159,930 110,535 — 110,535 
Agency bonds15,947 — 15,947 2,784 — 2,784 
Commercial paper— 22,654 22,654 — 7,004 7,004 
Derivative instruments
Currency hedging contracts (1)
— 2,163 2,163 — — — 
Total assets$345,990 $35,341 $381,331 $305,023 $15,280 $320,303 
Liabilities
Derivative instruments
Currency hedging contracts (1)
$— $347 347 $— $— — 
(1) Based on observable market transactions of spot currency rates, forward currency rates or equivalently-termed instruments. Carrying amounts of the financial assets and liabilities are equal to the fair value. As of September 30, 2023, the derivative assets and liabilities recorded within prepaid expenses and other current assets, prepaid expense and other assets and other long-term liabilities were $1.6 million, $0.6 million and $0.3 million, respectively.
We had no available for sale securities that were classified within Level 3 as of September 30, 2023 and December 31, 2022.
A contingent liability was assumed as part of the Antares acquisition related to TLANDO. The acquisition date fair value was measured using the income approach, specifically the probability weighted expected return method for the development milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and royalty payments. Estimates and assumptions used in the Monte Carlo simulation include forecasted revenues, cost of debt, risk free rate, weighted average cost of capital, revenue market price risk and revenue volatility. Estimates and assumptions used in the income approach include the probability of achieving certain milestones and a discount rate. These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. Changes in the fair value subsequent to the acquisition date will be recognized in our condensed consolidated statements of income. In September 2023, we provided Lipocine notice of termination of the TLANDO license agreement effective January 31, 2024. Based on the fair value remeasurement performed as of September 30, 2023, we recognized a gain on change in fair value of the contingent liability of $13.2 million for the three months ended September 30, 2023 in our condensed consolidated statements of income.